We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Microsoft Corp., UnitedHealth Group Inc., and The Charles Schwab Corp.
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 10, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (MSFT - Free Report) , UnitedHealth Group Inc. (UNH - Free Report) , and The Charles Schwab Corp. (SCHW - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Microsoft, UnitedHealth and Schwab
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., UnitedHealth Group Inc., and The Charles Schwab Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Microsoft have outperformed the S&P 500 over the past year (+44.1% vs. +24.9%), with the company benefiting from strength in its Azure cloud platform as well as an accelerated global digital transformation.
Continuation of remote work and mainstream adoption of the hybrid working model has been boosting Teams’ user growth. Microsoft has also been witnessing a surge in user base of its different applications including Microsoft 365 suite, Dynamics and Power Platform. Supply chain disruptions, increasing costs due to Azure enhancements and stiff competition in the cloud space are likely to dent margins, though.
UnitedHealth shares have gained +15.3% over the past three months against the Zacks Medical Insurance industry’s gain of +13.2%. The Zacks analyst believes that UnitedHealth has been witnessing strong growth across its Optum and UnitedHealthcare segments, which have, in turn, been driving revenues.
This momentum is likely to continue, in the quarters ahead, on the back of a strong market position, new deals, renewed agreements and expansion of service offerings. UNH's government business also remains well-poised for growth. The international business is expected to bounce back in terms of membership figures. Softness in commercial business due to the ongoing pandemic and rising operating expenses remain as major concerns, though.
Shares of Schwab have gained +33.8% in the last six months against the Zacks Investment Banking industry’s gain of +11.4%. The Zacks analyst believes that Schwab’s inorganic growth efforts and initiatives to augment trading revenues will keep boosting profitability.
Strategic acquisitions have not only established Schwab as a leading brokerage player, but will also be accretive to earnings. Offering commission-free trading has also led to a rise in client assets and brokerage accounts, thereby improving trading revenues. Lingering near-zero interest rates, with no chance of a hike in the near term and persistently increasing operating expenses, however, are some of the major headwinds.
Other noteworthy reports we are featuring today include NVIDIA Corp. (NVDA) and Diageo plc (DEO).
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
As one investor put it, “curing and preventing hundreds of diseases…what should that market be worth?” This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Microsoft Corp., UnitedHealth Group Inc., and The Charles Schwab Corp.
For Immediate Release
Chicago, IL – January 10, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corp. (MSFT - Free Report) , UnitedHealth Group Inc. (UNH - Free Report) , and The Charles Schwab Corp. (SCHW - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Microsoft, UnitedHealth and Schwab
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp., UnitedHealth Group Inc., and The Charles Schwab Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Microsoft have outperformed the S&P 500 over the past year (+44.1% vs. +24.9%), with the company benefiting from strength in its Azure cloud platform as well as an accelerated global digital transformation.
Continuation of remote work and mainstream adoption of the hybrid working model has been boosting Teams’ user growth. Microsoft has also been witnessing a surge in user base of its different applications including Microsoft 365 suite, Dynamics and Power Platform. Supply chain disruptions, increasing costs due to Azure enhancements and stiff competition in the cloud space are likely to dent margins, though.
(You can read the full research report on Microsoft here >>>)
UnitedHealth shares have gained +15.3% over the past three months against the Zacks Medical Insurance industry’s gain of +13.2%. The Zacks analyst believes that UnitedHealth has been witnessing strong growth across its Optum and UnitedHealthcare segments, which have, in turn, been driving revenues.
This momentum is likely to continue, in the quarters ahead, on the back of a strong market position, new deals, renewed agreements and expansion of service offerings. UNH's government business also remains well-poised for growth. The international business is expected to bounce back in terms of membership figures. Softness in commercial business due to the ongoing pandemic and rising operating expenses remain as major concerns, though.
(You can read the full research report on UnitedHealth here >>>)
Shares of Schwab have gained +33.8% in the last six months against the Zacks Investment Banking industry’s gain of +11.4%. The Zacks analyst believes that Schwab’s inorganic growth efforts and initiatives to augment trading revenues will keep boosting profitability.
Strategic acquisitions have not only established Schwab as a leading brokerage player, but will also be accretive to earnings. Offering commission-free trading has also led to a rise in client assets and brokerage accounts, thereby improving trading revenues. Lingering near-zero interest rates, with no chance of a hike in the near term and persistently increasing operating expenses, however, are some of the major headwinds.
(You can read the full research report on Schwab here >>>)
Other noteworthy reports we are featuring today include NVIDIA Corp. (NVDA) and Diageo plc (DEO).
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
As one investor put it, “curing and preventing hundreds of diseases…what should that market be worth?” This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.